Stage IIIB Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Active Not Recruiting2 IdentifierTitlePurposeDrugs
NCT02965716Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTreatment
NCT02500576Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaTreatment